Why partner with Open Innovation? 

We want to be the best scientific partners you have, helping you to translate your ideas into medicines for patients

Get email alerts on programme news & new compounds

What we are looking for in an Open Innovation partner

Our way of working at AstraZeneca is inclusive, open and collaborative. We aim to create mutually beneficial partnerships founded on trust and transparency.

Through Open Innovation, we want to work with scientists and researchers anywhere in the world that have a great idea and where we think we can help translate that idea into the medicines of the future. We work hard to ensure that both parties receive the greatest possible value from the relationship.

Configure Image Component
Configure Image Component

How we evaluate potential collaborations

We know it takes time to put a proposal together so we endeavour to give it the attention it deserves when evaluating potential collaborations.

All submissions undergo a thorough internal review process, with therapy, disease or technology experts alongside our Open Innovation team. This process may take up to 8 weeks and our decision will then be communicated back to you. For more information, please visit the Application Process page.

If you are looking for other partnering opportunities not listed here (i.e. licensing), please visit the AstraZeneca partnering page to learn more.

Top tips for success 

Configure Image Component

Make sure your proposal is clear

Configure Image Component

Familiarise yourself with the application process

Configure Image Component

Contact us if you have any questions

See how we have collaborated with our partners

Edit Video Component

Zubair Ahmed, Professor in Neuroscience, University of Birmingham, UK

Professor Ahmed outlines the collaborative approach taken through Open Innovation for repurposing a small molecule inhibitor from AstraZeneca’s clinic-ready compound library to investigate central nervous system repair.

Edit Video Component

Cecilia Rodrigues, Faculty of Pharmacy, University of Lisbon, Portugal

Professor Rodrigues shares her experience of collaborating through Open Innovation to identify active compounds for a known cell death target using AstraZeneca’s phenotypic screening library.

Configure Image Component

Explore our programmes and collaborate with us

We offer a number of programmes, from preclinical datasets and clinical compounds to real-time R&D challenges.

Modal Window Component Section Begins
Modal Window Component Section Ends